The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
Open accessAbstract
BACKGROUND: Whether closure of a patent foramen ovale is effective in the prevention of recurrent ischemic stroke in patients who have had a cryptogenic stroke is unknown. We conducted a trial to evaluate whether closure is superior to medical therapy alone in preventing recurrent ischemic stroke or early death in patients 18 to 60 years of age. METHODS: In this prospective, multicenter, randomized, event-driven trial, we randomly assigned patients, in a 1:1 ratio, to medical therapy alone or closure of the patent foramen ovale. The primary results of the trial were analyzed when the target of 25 primary end-point events had been observed and adjudicated. RESULTS: We enrolled 980 patients (mean age, 45.9 years) at 69 sites. The medical-therapy group received one or more antiplatelet medications (74.8%) or warfarin (25.2%). Treatment exposure between the two groups was unequal (1375 patient-years in the closure group vs. 1184 patient-years in the medical-therapy group, P=0.009) owing to a higher dropout rate in the medical-therapy group. In the intention-to-treat cohort, 9 patients in the closure group and 16 in the medical-therapy group had a recurrence of stroke (hazard ratio with closure, 0.49; 95% confidence interval [CI], 0.22 to 1.11; P=0.08). The between-group difference in the rate of recurrent stroke was significant in the prespecified per-protocol cohort (6 events in the closure group vs. 14 events in the medical-therapy group; hazard ratio, 0.37; 95% CI, 0.14 to 0.96; P=0.03) and in the as-treated cohort (5 events vs. 16 events; hazard ratio, 0.27; 95% CI, 0.10 to 0.75; P=0.007). Serious adverse events occurred in 23.0% of the patients in the closure group and in 21.6% in the medical-therapy group (P=0.65). Procedure-related or device-related serious adverse events occurred in 21 of 499 patients in the closure group (4.2%), but the rate of atrial fibrillation or device thrombus was not increased. CONCLUSIONS: In the primary intention-to-treat analysis, there was no significant benefit associated with closure of a patent foramen ovale in adults who had had a cryptogenic ischemic stroke. However, closure was superior to medical therapy alone in the prespecified per-protocol and as-treated analyses, with a low rate of associated risks. (Funded by St. Jude Medical; RESPECT ClinicalTrials.gov number, NCT00465270.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
Dennis, M. S. (1996) · The Lancet · Cited by 2,728
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
Furlan, A. J., Reisman, M., Massaro, J., Mauri, L., Adams, H., Albers, G. W., Felberg, R., Herrmann, H., Kar, S., Landzberg, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1009639 · Cited by 1,060
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
Meier, B., Kalesan, B., Mattle, H. P., Khattab, A. A., Hildick-Smith, D., Dudek, D., Andersen, G., Ibrahim, R., Schuler, G., Walton, A. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211716 · Cited by 920
PATENT FORAMEN OVALE IN YOUNG STROKE PATIENTS
Webster, M. W. I., Smith, H. J., Sharpe, D. N., Chancellor, A. M., Swift, D. L., Bass, N. M., & Glasgow, G. L. (1988) · The Lancet · doi:10.1016/s0140-6736(88)92944-3 · Cited by 823
Krumsdorf, U., Ostermayer, S., Billinger, K., Trepels, T., Zadan, E., Horvath, K., & Sievert, H. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.10.030 · Cited by 596
Agarwal, S., Bajaj, N. S., Kumbhani, D. J., Tuzcu, E. M., & Kapadia, S. R. (2012) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2012.02.021 · Cited by 195
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Kitsios, G. D., Dahabreh, I. J., Dabrh, A. M. A., Thaler, D. E., & Kent, D. M. (2011) · Stroke · doi:10.1161/strokeaha.111.631648 · Cited by 137
Self-citation
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Hankey, G. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70255-2 · Cited by 384
Ischaemic stroke in young adults: risk factors and long-term consequences
Maaijwee, N. A. M. M., Rutten-Jacobs, L. C. A., Schaapsmeerders, P., van Dijk, E. J., & de Leeuw, F.-E. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.72 · Cited by 377
Metadata
- Authors
- Carroll, J. D., Saver, J. L., Thaler, D. E., Smalling, R. W., Berry, S., MacDonald, L. A., Marks, D. S., & Tirschwell, D. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-03-21
- Volume
- 368
- Issue
- 12
- Pages
- 1092-1100
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2103291158
- Cited by
- 983
- References
- 12
- FWCI
- 90.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke. https://app.cochat.ai/papers/10.1056/nejmoa1301440
- The paper
- Carroll, J. D., Saver, J. L., Thaler, D. E., Smalling, R. W., Berry, S., MacDonald, L. A., Marks, D. S., & Tirschwell, D. L. (2013). Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1301440
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.